期刊文献+

紫杉醇对p53突变型肺癌细胞株H322的生长抑制作用 被引量:2

Growth-inhibiting effects of paclitaxel on H322 cells-p53 mutant strain of human lung cancer cell
暂未订购
导出
摘要 目的:通过体外实验评价紫杉醇对p53突变型肺癌细胞株H322的生长抑制作用。方法:紫杉醇不同作用浓度不同作用时间处理H322细胞后,应用MTT法检测紫杉醇对肺癌细胞生长抑制作用,通过流式细胞术分析细胞周期及凋亡的变化,荧光显微镜观察细胞核形态的变化。结果:紫杉醇对H322的细胞毒性呈时间依赖性(P<0.05),(10-1000)nmol/L的浓度对H322生长抑制差异不显著(P>0.05)。浓度≤100nmol/L时,G2-M期比率随浓度增加而增高(P<0.05);凋亡比例在低浓度范围内(0.1-10)nmol/L呈浓度依赖性,浓度进一步增加,反而降低。时间依赖性实验中,10nmol/L作用时,凋亡发生呈时间效应;G2-M期所占比例在12h达最高。1000nmol/L作用时,G2-M期阻滞程度和持续时间均高于10nmol/L,但不如低浓度诱导凋亡出现得早。典型凋亡细胞出现浓缩、成片的染色质。紫杉醇诱导的凋亡和G2-M期阻滞无相关性(P>0.05)。结论:体外实验中,紫杉醇对H322细胞有明显生长抑制作用,并且这种作用呈时间依赖性,但在一定浓度范围内剂量效应不明显;低浓度紫杉醇虽然对G2-M期阻滞影响较小,却能比高浓度更早诱发凋亡,延长作用时间亦可达到有效抑制肿瘤细胞增殖的目的。 Objective:To assess the growth -inhibiting effects of paclitaxel on human lung cancer H322 cell line in vitro. Methods: H322 cells were exposed to paclitaxel at different concentration and different treating time, then the growth inhibiting effects of the cell line were detected with MTT assay, and the change of the cell cycle and apoptosis were analyzed with flow cytometry. Fluorescence microscopy was used to observe the nucleolus change stained by Hoechst33342. Results: The growth - inhibiting effect of paclitaxel on H322 cells was time dependent(P 〈 0.05). The inhibition effects caused by paclitaxel from 10nmol/L to 1000nmol/L had not significant difference(P 〉 0.05 ). At the concentration -dependent experiment, the proportion of apoptosis was highest at 10nmol/L paclitaxel, while the percentage of G2 - M phase increased in accordance with raise of the paclitaxel concentration, when paclitaxel concentration changed from 0.1 nmol/L to lOOnmol/L(P 〈 0.05). At the time - dependent experiment, the inducement of apoptosis was time dependent(P 〈0.05) and the percentage of G2 - M phase was highest at 12h when pacli- taxel was 10nmol/L. Compared to 10nmol/L paclitaxel, 1000nmol/L paclitaxel could induce a higher degree and du- ration of G2 - M arrest and a later apoptosis. Apoptosis had no relationship with G2 - M arrest(P 〉0.05). The typical apoptotic cells with condensed and fragmented chromatin could be observed in cells treated by paclitaxel under Fluorescence microscopy. Conclusion: Paclitaxel inhibits the growth of H322 cells in vitro in time - dependent manner. It can induce apoptosis and G2 - M arrest but the later two have no relationship between each other. Low con- centration paclitaxel can also inhibit effectively the growth of H322 ceils by prolonging treatment.
出处 《现代肿瘤医学》 CAS 2008年第6期900-903,共4页 Journal of Modern Oncology
关键词 肺癌 紫杉醇 P53 细胞凋亡 细胞周期 lung neoplasms paclitaxel p53 apoptosis cell cycle
  • 相关文献

参考文献10

  • 1Fisher MD. Strategies to restore p53 function in patients with lung cancer[ J]. Clin Lung Cancer,2001,3 (2) :99 - 101.
  • 2Chan KT, Lung ML. Mutant p53 expression enhances drug resistante in a hepatocellular carcinoma cell line [ J ]. Cancer Chemother Pharmacol, 2004,53(6): 519-526.
  • 3Roth JA, Grammer SF. Gene replacement therapy for non - small cell lung cancer: a review [ J ]. Hematol Oncol Clin North Am, 2004,18( 1 ) :215 -229.
  • 4芮萌,李龙芸,刘长庭.几项生物学指标与肺癌患者5年生存率的相关性分析[J].中国临床康复,2006,10(28):67-69. 被引量:5
  • 5Long BH, Fairchild CR. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase [J]. Cancer Res,1994,54(16) :4355 -4361.
  • 6Jordan MA, Toso RJ, Thrower D, et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations[J]. Proc Natl Acad Sci USA, 1993,90(10) :9552 -9556.
  • 7Wang TH, Wang HS, Soong YK. Paclitaxel - induced cell death : where the cell cycle and apoptosis come together [ J ]. Cancer, 2000,88( 11 ) :2619 -2628.
  • 8Pushkarev VM, Starenki DV, Saenko VA, et al. Molecular mechanisms of the effect of low concentrations of taxol in anaplastic thyroid cancer cells[J]. Endocrinology, 2004,145:3143 -3152.
  • 9Lin HL, Chang YF, Liu TY, et al. Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase [J]. Aticancer Res, 1998, 18(5A):3443-3450.
  • 10Li W, Fan J, Banerjee D, et al. Overexpression of p21 ( waft ) decreases G2 - M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein [ J]. Mol Pharmacol, 1999,55 : 1088 - 1093.

二级参考文献12

  • 1Haque AK,Syed S,Lele SM,et al.Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer:strong thyroid transcription factor-1 expression predicts better survival.Appl Immunohistochem Mol Morphol 2002;10(2):103-9
  • 2Rostad H,Naalsund A,Strand TE,et al.Results of pulmonary resection for lung cancer in Norway,patients older than 70 years.Eur J Cardiothorac Surg2005;27(2):325-8
  • 3Xavier F,Henn Ld A,Oliveira M,et al.Smoking and its relation to the histological type,survival,and prognosis among patients with primary lung cancer.Rev Paul Med 1996;114:1298-302
  • 4Ebina M,Steinberg SM,Mulshine JL et al.Relationship of p53 overexpression and up-regula-tion of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.Cancer Res 1994; 54(9):2496-503
  • 5Nonaka M,Kadokura M,Yamamoto S,et al.Tumor dimension and prognosis in surgically treated lung cancer:for intentional limited resection.Am J Clin Oncol 2003;26(5):499-503
  • 6Iizasa T,Suzuki M,Yasufuku K,et al.Preoperative pulmonary function as a prognostic factor for stage I non-small cell lung carcinoma.Ann Thorac Surg2004;77(6):1896-902
  • 7Dworakowska D,Jassem E,Jassem J,et al.Prognostic relevance of altered pRb and p53 protein expression in surgically treated non-small cell lung cancer patients.Oncology 2004;67(1):60-6
  • 8Chapelier A,Fadel E,Macchiarini P,et al.Factors affecting long-term survival after en-bloc resection of lung cancer invading the chest wall.Eur J Cardiothorac Surg 2000;18(5):513-8
  • 9Mitsudomi T,Hamajima N,Ogawa M,et al.Prognostic significance of p53alterations in patients with non-small cell lung cancer:a meta-analysis.Clin Cancer Res 2000;6(10):4055-63
  • 10Endo K,Terada T.Protein expression of CD44 (standard and variant isoforms)in hepatocellular carcinoma:relationships with tumor grade,clinicopathologic parameters,p53 expression,and patient survival.J Hepatol 2000; 32(1):78-84

共引文献4

同被引文献34

  • 1钱军,秦叔逵,唐庆庆,陈映霞,杨柳青.吉非替尼治疗晚期难治性小细胞肺癌合并急性上腔静脉综合征[J].临床肿瘤学杂志,2005,10(3):243-244. 被引量:9
  • 2Ferraldeschi R,Baka S,Jyoti B,et al.Modern management of small-cell lung cancer[J].Drugs,2007,67 (15):2135-2152.
  • 3O'Brien ME,Ciuleanu TE,Tsekov H,et al.Phase Ⅲ trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer[J].J Clin Oncol,2006,24(34):5441-5447.
  • 4Curtis KK,Hartney JT,Jewell RC,et al.A Phase Ⅰ study to characterize the safety,tolerability,and pharmacokinetics of topotecan at 4mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer[J].J Clin Pharmacol,2010,50(3):268-275.
  • 5Eckardt JR,von Pawel J,Papai Z,et al.Open-label,multicenter,randomized,phase Ⅲ study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapynaive patients with extensive-disease small-cell lung cancer[J].J Clin Oncol,2006,24(13):2044-2051.
  • 6Ardizzoni A,Manegold C,Debruyne C,et al.European organization for research and treatment of cancer (EORTC)08957 phase Ⅱ study of topotecan in combination with cisplatin as second line treatment of refractory and sensitive small cell lung cancer[J].Clin Cancer Res,2003,9:143-150.
  • 7Onoda S,Masuda N,Seto T,et al.Phase Ⅱ trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer:Thoracic Oncology Research Group Study 0301[J].J Clin Oncol,2006,24 (34):5448-5453.
  • 8Kaira K,Sunaga N,Tomizawa Y,et al.A Phase Ⅱ study of amrubicin,a synthetic 9-aminoanthracycline,in patients with previously treated lung cancer[J].Lung Cancer,2010,69(1):99-104.
  • 9Ettinger DS,Jotte R,Lorigan P,et al.Phase Ⅱ study of amrubicin as second-line therapy in patients with platinum refractory small-cell lung cancer[J].J Clin Oncol,2010,28 (15):2598-2603.
  • 10Inoue A,Sugawara S,Yamazaki K,et al.Randomized phase Ⅱ trial comparing amrubicin with topotecan in patients with previous ly treated small cell lung cancer:North Japan Lung Cancer Study Group Trial 0402[J].J Clin Oncol,2008,26 (33):5401-5406.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部